Hospitex International

What Hospitex International does

Hospitex International S.r.l. is an Italian cytology diagnostics company headquartered in Sesto Fiorentino, Florence, operating as the cytology arm of Aliko Scientific Group following its 2024 acquisition by NASDAQ-listed Ikonisys. The company has a 50+ year operating history (founded 1971 in Geneva, relocated to Italy in 1980) and employs 11-50 people, with its CYTOfast technology installed across 42 countries and 3,850+ cumulative customers, performing 50M+ tests cumulatively. Its core product is the CYTOfast System, a Liquid Based Cytology (LBC) platform built on patented Nephelometric Smart Technology (NST) that produces filter-less, standardized single-layer monolayer slides while preserving cell-cluster morphology, using a methanol-free fixative that preserves samples for at least eight weeks at room temperature. The platform is complemented by the CYTOfast Biobank (up to 200 slides per sample), specialized screening kits (Urine24 for bladder cancer, PapTest24 for cervical screening, Vet24 for veterinary use), the BLOCKfast histology product, and the Hospitex Digital Pathology (HDP) platform, which integrates hardware, software, AI-assisted pre-analysis, blockchain-notarized reports, and TESI-based LIS workflows into a single end-to-end solution. Hospitex Labs provides turnkey owned, franchised, and custom cytology laboratories, with the Sesto Fiorentino reference site operational since 2022.

The company monetizes through a closed-system razor-and-blade model: hardware sales of processors, stainers, cytocentrifuges, and digital microscopes, paired with high-margin recurring revenue from proprietary consumables (slides, reagents, fixatives, collection vials). Distribution combines enterprise field sales (winning public tenders such as the 5-year Federico II di Napoli contract), an exclusive international distributor network with 80%+ territory penetration requirements, lab franchising fees, and an emerging B2C e-commerce channel via Urine24.com and Italian pharmacies. Customer segments span pathology laboratories and hospitals, gynecologists, individual consumers, distributors, healthcare networks and governments, and veterinary practices. Upcoming catalysts include the June 2026 launch of Cytofast Auto (a fully automated processor co-developed with Dobot Robotics), the 2026 release of Hospitex's first urinary cytology AI dataset, and a stated pipeline of four preliminary M&A targets under a new Group CEO appointed in February 2026.

Name

Hospitex International

Legal name

Hospitex International S.r.l.

Website

https://hospitex.com

Company type

Private

Founded year

1971

Operating status

Operating

Headcount range

11–50 employees

Short description

Hospitex International is an Italian cytology diagnostics company that develops the CYTOfast liquid-based cytology platform, proprietary consumables, and an integrated digital pathology platform, serving pathology labs, hospitals, healthcare networks, distributors, and consumers across 42+ countries as the cytology arm of Aliko Scientific Group.

Ownership category

akta.pro rank

Product category

Clinical Diagnostic Laboratory Equipment

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

Keywords

• Liquid based cytology
• Digital pathology
• Cancer screening kits
• Cytology laboratory equipment
• Anatomical pathology diagnostics

Headquarters

HQ city

Sesto Fiorentino

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. CYTOfast Hardware Instruments: Sale of CYTOfast System instruments including Processor, Automated Stainer, Cytocentrifuge, and Digital Microscope. These capital equipment sales generate significant upfront revenue and create long-term customer lock-in.
2. Recurring Consumables: Closed system model generating recurring revenues from proprietary disposables (slides, reagents, fixatives, collection vials) for years after instrument installation. Once a customer base is acquired, it represents stable future value. The company claims best CAPEX and OPEX pricing in the market.
3. Hospitex Labs Services: Turnkey laboratory services including owned, franchised, and custom cytology laboratories. Revenue generated from laboratory service fees, franchise royalties, and technical partnership arrangements. The first lab opened in Sesto Fiorentino in 2022 serves as a franchise model replicable worldwide.
4. Urine24 Direct-to-Consumer Screening: B2C urine cancer screening kits sold online and through pharmacies, with home sample collection, courier logistics, and digital reporting included. First e-shop B2C online for urinary cytology testing launched in 2025.
5. Digital Pathology Platform Subscription: HDP platform revenue including hardware, software, AI integration, OS, sensitive data management, and dashboard — offered as an integrated all-in-one solution. Remote pathologist reporting as a service from Italy is also included.
6. International Distribution Rights: Distribution agreements with international partners for exclusive rights in specific territories. The Italy distribution deal with Naturneed involves minimum sales targets. Each commercial opportunity in target markets carries potential annual revenue of €200,000 to €2 million.
7. M&A and Portfolio Expansion: Strategic acquisitions aligned with the Group's industrial plan focusing on portfolio strengthening. Preliminary discussions with four companies for potential M&A transactions. In 2024, Ikonisys acquired Hospitex with issuance of 2M new shares to ETH Scientific.

Go-to-market motion4 records

Distribution channels7 records

Marketing channels10 records

Core offering

Hospitex International designs, manufactures, and sells the CYTOfast System — a patented liquid-based cytology (LBC) platform using Nephelometric Smart Technology (NST) to produce standardized thin-layer monolayer cytology slides for pathology laboratories and hospitals. The company sells the instrument hardware, proprietary consumables (slides, reagents, fixatives), and the integrated Hospitex Digital Pathology (HDP) software platform with AI-assisted analysis. It also operates turnkey cytology laboratories (Hospitex Labs franchising), provides ICT/telemedicine services, and sells direct-to-consumer cancer screening kits such as Urine24.

Product overview

Hospitex International operates as the Cytology Company of Aliko Scientific, offering a comprehensive ecosystem of products and services for precision cytology diagnostics. The core product is the CYTOfast System, a liquid-based cytology (LBC) platform utilizing proprietary Nephelometric Smart Technology (NST) to produce standardized thin-layer monolayer slides. This platform serves as the foundation for specialized screening solutions including CYTOfast Urine24 (bladder cancer screening), PapTest24 (cervical cancer screening), and CYTOfast Vet24 (veterinary applications). The CYTOfast Biobank module enables extended cell preservation for up to 200 slides per sample. Hospitex Digital Pathology (HDP) represents the company's integrated digital pathology platform combining hardware, AI-powered image analysis software, and services for the complete workflow from sampling to digital report. The upcoming Cytofast Auto (June 2026 launch) will add full automation capabilities. Beyond products, Hospitex operates Hospitex Labs (turnkey laboratory franchise model), provides ICT services including the WaidX telemedicine platform, and runs the Hospitex Learning Center for professional education in cytology techniques including The Paris System for urinary cytology reporting.

Differentiator

Problem solved

Functional benefit

Brands

• CYTOfast System: The leading system for Liquid Based Cytology (LBC), featuring proprietary Nephelometric Smart Technology for thin-layer cytology processing.
• CYTOfast Biobank
• BLOCKfast
• Hospitex Labs
• CYTOfast Urine24
• CYTOfast Vet24
• PapTest24
• Hospitex Digital

Products and services

• CYTOfast System Patented liquid-based cytology (LBC) platform using Nephelometric Smart Technology (NST) to produce standardized thin-layer monolayer slides for any target organ. Includes the processor, automated stainer, cytocentrifuge, and digital microscope. Sold to pathology laboratories and hospitals with a closed-system consumables model.
• Hospitex Digital Pathology (HDP) Platform End-to-end integrated digital pathology platform from initial cytological sampling to final patient report, combining hardware (CYTOfast System, digital microscope), software (image management, AI-assisted analysis), blockchain-notarized reports, GDPR-compliant data management, and remote pathologist reporting as a service.
• CYTOfast Urine24 Over-the-counter bladder and urinary tract cancer screening kit. Consumers collect a urine sample at home, ship via courier, and receive digital Paris System reporting within 24-48 hours of lab receipt. Sold via Urine24.com and Italian pharmacies.
• PapTest24 Liquid-based thin-layer Papanicolaou (Pap) test for cervical cancer screening using CYTOfast technology and The Paris System reporting, with same-day results via the digital pathology platform. Sold to gynecologists and women's health providers.
• CYTOfast Vet24 Veterinary cytology solution for early cancer diagnosis in animals, applying the CYTOfast LBC technology in animal health settings.
• CYTOfast Biobank Biobank solution enabling residual cell preservation for up to 200 slides per sample, with cells maintained at room temperature for up to 8 weeks without methanol, allowing re-testing and follow-on molecular biology analysis.
• Hospitex Labs (Turnkey Laboratory Services and Franchising) Turnkey cytological analysis laboratory services offered as owned, franchised, or custom laboratory solutions. The first franchise lab opened in Sesto Fiorentino in 2022 and serves as a replicable model that can be established in approximately 3 months anywhere in the world.
• ICT Services for Pathological Anatomy IT services for anatomical pathology laboratories, including software management (in partnership with TESI Group), network infrastructure, dedicated servers, AI reading support, custom IT solutions, and the WaidX telemedicine platform.
• Cytofast Auto Fully automated universal monolayer liquid-based cytology processor co-developed with Dobot Robotics, designed for large-scale routine cytology processing to reduce operational costs and expand the addressable market.
• BLOCKfast Industrial product line for anatomical pathology workflows within the Hospitex Industrial division.

Quantifiable outcome

• 90% reduction in interpretation time
• +9 more outcomes

Named customers10 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature14 records

Partnerships

20 partnerships are on record, tiered core and minor.

• NaturneedcoreChannel Partner/ Reseller/ Distributor · 10 March 2026Distribution agreement signed in March 2026 for commercialization of Urine24, a bladder cancer screening test, in Italy. The deal involves minimum sales targets and supports Aliko Scientific's expansion strategy amid recent financing activities.
• Dobot RoboticscoreTechnology or Integration · 4 December 2025Collaboration with Dobot Robotics for the development of Cytofast Auto, a fully automated universal monolayer cytology processor. The system aims to revolutionize cytology workflows by offering broad sample processing capabilities, cost efficiency, and market expansion potential.
• SwimCountminorChannel Partner/ Reseller/ Distributor · 27 November 2025Hospitex is the exclusive Italian distributor for SwimCount, a male fertility test. Hospitex launched a dedicated website for the product in November 2025.
• Menarini DiagnosticscoreChannel Partner/ Reseller/ Distributor · 6 June 2025Exclusive distribution partnership in Italy for diagnostic products. Described as a strategic milestone for Hospitex's commercial expansion in the Italian market.
• LILT Firenze (Lega Italiana per la Lotta contro i Tumori)coreGTM or Marketing Partner · 28 January 2025Joint cancer screening campaign for urinary tract tumors using Urine24 kits. LILT distributes kits through its screening activities and receives a portion of proceeds. The partnership aims to promote early bladder cancer diagnosis, targeting people over 50 (especially men), smokers, those with family history, and those exposed to pollutants.
• SYNLAB ItaliaminorStrategic or Co-development Partner · 4 November 2024Collaboration between Ikonisys and SYNLAB Italia in oncology diagnostics, welcomed by Hospitex as a strategic step forward in diagnostic oncology services in Italy.
• BIO BRASIL BIOTECNOLOGIA LTDAcoreChannel Partner/ Reseller/ Distributor · 10 September 2024MOU signed for significant expansion in Brazil's cytology market. BIO BRASIL to acquire 10 additional CYTOfast Plus systems and 50,000 reagent kits, expanding from 7 existing systems. A FISH (fluorescence in situ hybridization) pilot project is planned for the centralized BIO BRASIL laboratory. The partnership is effective for two years and aims to promote innovations in diagnostic pathology.
• CytosensminorStrategic or Co-development PartnerPartner at Cytopathology Conference organized by Prof. Giancarlo Troncone at University of Naples Federico II. Collaboration in molecular cytopathology education and scientific exchange.
• TESI GroupcoreTechnology or IntegrationTESI Group is described as the world's most advanced laboratory information management software for Anatomical Pathology. Hospitex Digital offers integration of TESI software with its hardware and platform solutions for complete laboratory digitalization.
• Asian Development Bank (ADB)minorGTM or Marketing PartnerADB supported Study Tour Health 2025 (September 2025) in which Hospitex was selected as a showcase company. Health ministry delegations from Thailand, Philippines, Uzbekistan, and Tajikistan visited Hospitex facilities. ADB has invested over $38 billion in the Asia-Pacific healthcare sector between 2023-2025.
• ICE Agency (Agenzia per la promozione all'estero e l'internazionalizzazione delle imprese italiane)minorGTM or Marketing PartnerICE Agency organized Hospitex's participation in Study Tour Health 2025 and Italian delegations at MEDICA trade fair. ICE supports Italian medical device companies' international expansion.
• Italian Ministry of Economy and Finance (MEF)minorGTM or Marketing PartnerMEF promoted Study Tour Health 2025, selecting Hospitex as one of the Italian healthcare companies to host international delegations for international cooperation in healthcare.
• University of FlorenceminorStrategic or Co-development PartnerAcademic collaboration in R&D for cytology diagnostics and AI training. One of several university partnerships supporting Hospitex's research programs.
• University of Bologna (Chieti campus)minorStrategic or Co-development PartnerAcademic R&D partnership contributing to Hospitex's continuous product development and patent portfolio.
• Fondazione ISPROminorStrategic or Co-development PartnerItalian cancer research foundation collaborating with Hospitex on R&D and diagnostic innovation.
• National Research Council (CNR) — ItalyminorStrategic or Co-development PartnerItalian National Research Council partnership for research and development in diagnostic technologies.
• Toscana Life SciencesminorStrategic or Co-development PartnerTuscan biomedical cluster partnership supporting Hospitex's innovation and development programs.
• European Laboratory for Non-Linear Spectroscopy (LENS)minorStrategic or Co-development PartnerScientific research collaboration with LENS on advanced spectroscopy and imaging technologies for cytology diagnostics.
• Società Cooperativa PathoxphereminorStrategic or Co-development PartnerPathology research cooperative collaborating with Hospitex on cytology quality standards and best practices.
• IkonisyscoreOthersIkonisys acquired Hospitex International in 2024 through issuance of 2M new shares to ETH Scientific. Hospitex is the cytology company of Aliko Scientific Group, which is under Ikonisys. Ikonisys provides the Ikoniscope MAX robotic microscope for automated FISH analysis, featured at the 36th European Congress of Pathology in Florence.

Scale indicators20 records

Recent moves9 records

Expansion highlights7 records

Broad incumbents

• Roche Diagnostics: Roche offers the uPath digital pathology platform and broader IVD/cancer diagnostics portfolio. Overlaps with Hospitex Digital Pathology and addresses similar hospital pathology customers as part of a much larger diagnostic franchise.
• Leica Biosystems (Danaher): Leica's Aperio digital pathology scanners and histology workflow solutions compete with Hospitex Digital Pathology and CYTOfast Plus for hospital pathology lab budgets. Operates as part of Danaher's broader life sciences platform.
• Philips Digital Pathology: Philips IntelliSite Pathology Solution is a major digital pathology platform competing with HDP. Targets large hospital networks with integrated imaging, workflow, and AI-ready architecture.
• Sysmex: Sysmex is a major IVD and hematology/cytology diagnostics company with global reach. Competes with Hospitex in clinical cytology, urine sediment analysis, and broader laboratory automation markets.

Direct peers

• Hologic: Hologic's ThinPrep is the dominant liquid-based cytology system globally, directly competing with Hospitex's CYTOfast. Both serve pathology labs with thin-layer slide preparation technology, automated staining, and increasingly digital pathology workflows.
• Becton Dickinson (BD): BD's SurePath is the other major LBC platform competing with CYTOfast. Both companies sell closed-system cytology instruments with proprietary consumables, targeting hospital pathology labs and cervical cancer screening programs.
• 3DHISTECH: 3DHISTECH is a direct digital pathology competitor offering whole-slide scanners, PACS, and AI-ready workflow software. Targets the same pathology lab segment as Hospitex's HDP platform, particularly in Europe.
• Sakura Finetek: Sakura Finetek provides histology and cytology instruments, reagents, and tissue processors that compete with CYTOfast System and BLOCKfast in anatomical pathology labs, particularly in Europe.
• Hamamatsu Photonics: Hamamatsu's NanoZoomer whole-slide scanners are widely used in digital pathology and compete with Hospitex's digital microscope and HDP scanner components for hospital lab installations.

Emerging players

• Ibex Medical Analytics: Ibex is an emerging AI pathology company focused on cancer detection algorithms deployed on existing digital pathology platforms. Represents both a potential partner (AI integration into HDP) and a competitive threat to Hospitex's in-house AI dataset approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=DkF3c7FFdNA
• LinkedInlinkedin.com/company/hospitex-international-srl/jobs
• Xx.com/Hospitex_Int
• Facebookfacebook.com/hospitex.international

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hospitex International